Rheumatoid Arthritis (RA) is an autoimmune chronic disease that is characterized by the positivity of various antibodies, the most specific being autoantibodies against citrullinated antigens (ACPA). Despite ACPA are not arthritogenic by themselves, ACPA positive individuals have high risk of RA development and ACPA positivity is associated with severe erosive phenotype and higher mortality rate compared to seronegative RA. Moreover, ACPA status is associated with favorable response to biologics targeting pathways involving autoantibody producing cells as B lymphocytes. In the current review we have discussed the pros and cons on the available scientific evidences, regarding the diagnostic, prognostic and management implications of ACPAs in RA.
|Titolo:||Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons|
|Citazione:||Alivernini, S., Galeazzi, M., Peleg, H., Tolusso, B., Gremese, E., Ferraccioli, G., et al. (2017). Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons. AUTOIMMUNITY REVIEWS, 16(11), 1096-1102.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|Is ACPA positivity the main driver for rheumatoid arthritis treatment.pdf||PDF editoriale||NON PUBBLICO - Accesso privato/ristretto||Administrator Richiedi una copia|